The estimated Net Worth of Joseph Iii Klein is at least $3.09 Million dollars as of 16 July 2024. Mr. Klein owns over 12,000 units of Ionis Pharmaceuticals Inc stock worth over $510,360 and over the last 19 years he sold IONS stock worth over $1,416,783. In addition, he makes $1,166,450 as Independent Director at Ionis Pharmaceuticals Inc.
Sign up
Mr. Klein IONS stock SEC Form 4 insiders trading
Joseph has made over 59 trades of the Ionis Pharmaceuticals Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 12,000 units of IONS stock worth $293,040 on 16 July 2024.
The largest trade he's ever made was exercising 30,000 units of Ionis Pharmaceuticals Inc stock on 29 February 2008 worth over $426,300. On average, Joseph trades about 3,074 units every 84 days since 2005. As of 16 July 2024 he still owns at least 12,000 units of Ionis Pharmaceuticals Inc stock.
You can see the complete history of Mr. Klein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joseph Klein biography
Joseph Klein, III, is an Independent Director of Isis Pharmaceuticals Inc. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a Venture Partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems. For over nine years from 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein has served on the boards of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds, since September 2007 and Akcea Therapeutics, Inc., a public biopharmaceutical company, since September 2019. Mr. Klein also serves on the boards of private and non-profit entities. The Board believes Mr. Klein is uniquely suited to serve on the Board and as Chairman of the Audit Committee because he is a Chartered Financial Analyst and has extensive public company, venture investment, board, and financial advisory expertise in the life sciences industry, including previously serving as Chairman of the Audit Committee at several public biopharmaceutical companies.
What is the salary of Joseph Klein?
As the Independent Director of Ionis Pharmaceuticals Inc, the total compensation of Joseph Klein at Ionis Pharmaceuticals Inc is $1,166,450. There are 9 executives at Ionis Pharmaceuticals Inc getting paid more, with Stanley Crooke having the highest compensation of $9,598,830.
How old is Joseph Klein?
Joseph Klein is 58, he's been the Independent Director of Ionis Pharmaceuticals Inc since 2005. There are 19 older and 5 younger executives at Ionis Pharmaceuticals Inc. The oldest executive at Ionis Pharmaceuticals Inc is Breaux Castleman, 79, who is the Independent Director.
What's Joseph Klein's mailing address?
Joseph's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Ionis Pharmaceuticals Inc
Over the last 9 years, insiders at Ionis Pharmaceuticals Inc have traded over $32,069,332 worth of Ionis Pharmaceuticals Inc stock. The most active insiders traders include Stanley T Crooke, B Lynne Parshall, and Michael R Hayden. On average, Ionis Pharmaceuticals Inc executives and independent directors trade stock every 8 days with the average trade being worth of $445,289. The most recent stock trade was executed by Richard S Geary on 28 August 2024, trading 651 units of IONS stock currently worth $32,159.
What does Ionis Pharmaceuticals Inc do?
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
What does Ionis Pharmaceuticals Inc's logo look like?
Complete history of Mr. Klein stock trades at Biomarin Pharmaceutical, Ionis Pharmaceuticals Inc, PDL Biopharma Inc, and Akcea Therapeutics Inc
Ionis Pharmaceuticals Inc executives and stock owners
Ionis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stanley Crooke,
Executive Chairman of the Board of Directors -
Brett Monia,
Chief Executive Officer, Director -
Richard Geary,
Senior Vice President - Development -
Elizabeth Hougen,
Senior Vice President, Finance and Chief Financial Officer -
Patrick O'Neil,
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary -
Joan Herman,
Director -
B. Lynne Parshall,
Director -
Dr. Brett P. Monia Ph.D.,
Founder, CEO & Director -
Dr. Stanley T. Crooke,
Scientific Advisor -
Joseph Klein,
Independent Director -
Joseph Wender,
Independent Director -
Spencer Berthelsen,
Independent Director -
Breaux Castleman,
Independent Director -
Frederick Muto,
Independent Director -
Michael Hayden,
Independent Director -
Joseph Loscalzo,
Independent Director -
Peter Reikes,
Independent Director -
B. Lynne Parshall Esq., J.D.,
Sr. Strategic Advisor & Director -
C. Frank Bennett,
Chief Scientific Officer -
Dr. Richard S. Geary,
Exec. VP & Chief Devel. Officer -
Elizabeth L. Hougen,
Exec. VP of Fin. & CFO -
Patrick R. O'Neil Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Eric E. Swayze Ph.D.,
Exec. VP of Research -
D. Wade Walke,
Investor Relations -
Onaiza Cadoret-Manier,
Chief Corporate Development and Commercial Officer -
Eric Swayze,
Senior Vice President - Research -
Dr. C. Frank Bennett,
Exec. VP & Chief Scientific Officer -
Darren Gonzales,
Chief Accounting Officer & Sr. VP -
Joel Edwards,
VP of Corp. Operations -
Damien Mc Devitt,
Chief Business Officer -
Sarah Boyce,
Chief Business Officer -
Joseph Baroldi,
EVP, Chief Business Officer -
Kyle Jenne,
EVP, Chf GL Pdt Str Ofcr -
Allene M. Diaz,
Director -
Brian Birchler,
EVP, Corp and Development Ops -
Eugene Schneider,
EVP, Chf Clinical Develop Ofcr -
Michael J. Yang,
Director